Summary
This 2025 Nature Cancer review by Awada et al. synthesises current evidence on the application and efficacy of neoadjuvant immunotherapy across diverse cancer types. The paper appears to document how treatment paradigms in oncology are shifting towards earlier immunotherapy administration (before definitive surgery or chemoradiotherapy) and reports on emerging clinical evidence supporting this approach. The work is positioned as a contemporary overview of a rapidly changing field in cancer treatment strategy.
UK applicability
As a clinical oncology review, the findings are directly relevant to NHS cancer treatment protocols and NICE guideline development in the United Kingdom. However, the applicability depends on UK access to immunotherapy agents, regulatory approval status, and health system capacity to deliver neoadjuvant regimens.
Key measures
Likely pathological complete response (pCR) rates, overall survival, disease-free survival, adverse event profiles, and immunotherapy response metrics across cancer histologies
Outcomes reported
The paper reviews the evolving evidence on neoadjuvant immunotherapy (administered before primary treatment) across multiple cancer types, examining clinical efficacy, patient outcomes, and emerging treatment paradigms. As suggested by the title and journal scope, the review likely synthesises data on response rates, pathological complete response, survival outcomes, and safety profiles.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.